The primary goal of the I-SPY 2 Trial is to identify and advance promising new treatments for breast cancer more efficiently. By focusing on pathological complete response (pCR) as an early indicator of treatment success, the trial aims to reduce the time and cost associated with bringing new therapies to market. Additionally, the trial seeks to personalize treatment by matching patients with drugs that are most likely to be effective for their specific cancer type.
